Table 1 Differing characteristics of the studies comparing the response rates in HBeAg-positive patients
From: How to compare antivirals in the treatment of chronic hepatitis B?
|  | Pegylated-IFN-α2a, 180 μg once Weekly [8] | Lamivudine 100 mg/d | Adefovir 10 mg/d [11] | Entecavir 0.5 mg/d [9] | Telbivudine 600 mg/d [10] | Tenofovir 300 mg/d [12] |
|---|---|---|---|---|---|---|
Mean age (years) | 32.5 | 31.6 to 35 | 34 | 35 | 32 | 34 |
Male gender (%) | 79 | 74 to 79 | 76 | 77 | 74 | 68 |
Asian race (%) | 87 | 57 to 87 | 60 | 58 | 82 | 36 |
Patient number | 271 | 272 to 463 | 171 | 354 | 399 | 176 |
Previous treatment | Conventional IFN 11%, lamivudine 11% | Conventional IFN 11%/IFN 13% and lamivudine 3%/NA | IFN (24% among all arms) | IFN 13% and lamivudine 3% | NA | IFN 17%, lamivudine or emtricitabine 5% |
Baseline HBV-DNA (log10 cp/ml) | 9.9 | 9.5 to 10.1 | 8.25 | 9.62 | 9.51 | 8.64 |
Baseline ALT | 114.6 | 102 to 159 | 139 | 140.5 | 146 | 142 |
Baseline necro-inflammatory score | NA | 7.3 to 7.7 | 7.37 | 7.8 | 7 | 8.3 |
Baseline fibrosis score | NA | 2.2 to 2.3 | 1.64 | 2.3 | 2.2 | 2.3 |
Genotypes (%, A/B/C/D/others) | 8/28/60/3/1 | 7/30/58/4/1 (ref 8) 28/22/25/15/11 (ref 9) | NA | 27/19/31/10/13 | NA | 24/14/25/32/5 |
Treatment duration (weeks) | 48 | 48 to 52 | 48 | 48 | 52 | 48 |
Virological response criterion (HBV DNA level) | <400 cp/ml | <400 cp/ml (ref 8), <0.7 MEq/ml (ref 10), <300 cp/ml (ref 10) | <300 cp/ml | <0.7 MEq/ml | <300 cp/ml | <400 cp/ml |